Z-Asp-CH2-DCB

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Z-Asp-CH2-DCB 是一种不可逆的广谱 caspase 抑制剂。

Z-Asp-CH2-DCB is an irreversible inhibitor of broad spectrum caspase.(In Vitro):Z-Asp-CH2-DCB (10-100 μM) dose-dependently blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in SEB-stimulated (200 ng) PBMC. Z-Asp-CH2-DCB suppresses the production of the chemokines MCP-1, MIP-1α, and MIP-1β. Z-Asp-CH2-DCB inhibits TSST-1-activated PBMC and reduces IL-1β, IL-6, TNF-α, IFN-γ, MCP-1, MIP-1α, and MIP-1β to 10, 36, 25, 10, 11, 25, and 30%, respectively.(In Vivo):SU5416-induced septal cell apoptosis prevented byZ-Asp-CH2-DCB (1 mg; i.p.; every day for 3 weeks).

Z-Asp-CH2-DCB (10-100 μM) blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in SEB-stimulated (200 ng; 16 hours) PBMC in a dose-dependent manner. The production of the chemokines MCP-1, MIP-1α, and MIP-1β was also suppresses. The inhibitory effect of Z-Asp-CH2-DCB on TSST-1-activated PBMC is similar, reducing IL-1β, IL-6, TNF-α, IFN-γ, MCP-1, MIP-1α, and MIP-1β to 10, 36, 25, 10, 11, 25, and 30%, respectively, of levels in untreated cells.Z-Asp-CH2-DCB (10-100 μM; 48 hours) inhibits T-cell proliferation in PBMC stimulated with 200 ng of SEB/ml .Cell Viability Assay Cell Line:Human peripheral blood mononuclear cells Concentration:10, 50, 100 μM Incubation Time:48 hours Result:Inhibited T-cell proliferation in PBMC stimulated with SEB.

Z-Asp-CH2-DCB (1 mg; i.p.; every day for 3 weeks) prevents SU5416-induced septal cell apoptosis. Animal Model:Male Sprague-Dawley rats (SU5416+ Z-Asp-CH2-DCB group)Dosage:1 mg Administration:Intraperitoneal injection; every day for 3 weeks Result:The caspase 3-like activity in SU5416-treated rat lungs is significantly higher, whereas lungs from rats treated with SU5416+Z-Asp-CH2-DCB showed no increase in apoptotic activity.

——

NF-κB

NOD

AMPAR

——

——

153088-73-4

454.26

C20H17Cl2NO7

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (220.14 mM)

OC(=O)C[C@H](NC(=O)OCc1ccccc1)C(=O)COC(=O)c1c(Cl)cccc1Cl

——

(-20℃)

With Ice Pack

≥ 2 years